

**Remarks:**


By the present amendment, Applicants have made editorial changes to the description of Figures 8 and 9 in the Brief Description of the Drawings, to correspond to the changes made to the drawings in response to the Notice of Drawing Requirements which is simultaneously being filed herewith. It is submitted that the changes do not introduce any new matter and entry is respectfully requested.

If there are any fees due in connection with the filing of this amendment, including any fees required for an extension of time under 37 CFR 1.36, such an extension is requested and the fees should be charged to our Deposit Account No. 02-2095.

Attached hereto is a marked-up version of the changes made by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

**Gary Levy and David A. Clark**

  
Anita Nador (Reg No 47,366)

  
Micheline Gravelle  
Registration No. 40,261

Dated: March 12, 2002

Bereskin & Parr  
Box 401, 40 King Street West  
Toronto, Ontario, Canada  
M5H 3Y2

(416) 364-7311

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Disclosure:**

Paragraph beginning at page 5, line 7 has been amended to read as follows:

--Figure 8A shows the nucleotide sequence of the mouse (SEQ.ID.NO.: 10) and human (SEQ.ID.NO.: 11) Fgl2 gene promoter regions;

Figure 8B shows the nucleotide sequence of the mouse (SEQ.ID.NO.: 10) and human (SEQ.ID.NO.: 11) Fgl2 gene promoter regions:--

Paragraph beginning at page 5, line 9 has been amended to read as follows:

--Figure 9A shows the nucleic acid sequence of the transcription binding sites in the putative promoter region of hfgl2 (SEQ.ID.NO.: 12);

Figure 9B shows the nucleic acid sequence of the transcription binding sites in the putative promoter region of hfgl2 (SEQ.ID.NO.: 12):--